Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
No named decision-maker yet.
No careers mailbox known
Sep 30
Posted a role Director or Senior Director, Business Development
Sep 29
Manager or Senior Manager, Patient Recruitment and Retention crossed 45 days open
Sep 28
Closed a role Senior Specialist or Manager, Quality Systems · Senior Director, Outcomes, Value & Access crossed 45 days open
Sep 26
Posted 26 roles Senior Manager or Associate Director, Strategic Sourcing, Director, Trial Master File
26 open
$283k stated pay, 26 roles
truth B 75 100% stale
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and KRAS-driven cancers.
No named decision-maker yet.
Careers mailbox is known
Sep 27
Moved to Greenhouse
Relay Therapeutics® puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities.
No named decision-maker yet.
Careers mailbox is known
Sep 29
Closed a role Senior Manager, Drug Substance
Sep 28
Clinical Project Manager crossed 90 days open
Sep 26
Posted 9 roles Clinical Project Manager, VP, Head of Drug Discovery
Sep 20
Manager/Senior Manager, Pharmaceutics and Drug Product crossed 45 days open
8 open
+1 this week
$237k stated pay, 8 roles
Discover how Day One Biopharmaceuticals is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
No named decision-maker yet.
Careers mailbox is known
Sep 26
Moved to Greenhouse
We at Boundless Bio are pioneers in understanding and treating the most intractable cancers. We have charted a new spatial map of the cancer genome within cancer cells and are harnessing our scientific founders’ discoveries about.
Zachary Hornby · Director, Executive Officer · decision-maker
Christine Brennan Ph.D. · Director
Jennifer Lew · Director
Fabio Pucci Ph.D. · Director
Careers mailbox is known
Apr 5, 2023
Raised a round Series C $100M · SEC Form D
2018
Founded
Delphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation.
No named decision-maker yet.
Careers mailbox is known
May 26
New executive Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer · delphiatx.com
Apr 8, 2025
Recognition Delphia Therapeutics Named to Boston Business Journal's 2025 Best Places to Work · delphiatx.com
May 2, 2024
Launched GENETIC ENGINEERING NEWS: The Upside Down: Delphia Therapeutics Launches to Treat Cancer with Activation Lethality · delphiatx.com
Pushing the envelope: Our mission is to cure cancer and restore life to every patient everywhere.
No named decision-maker yet.
Careers mailbox is known
Jan 4, 2021
Raised a round Series A $77M
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver life-changing benefits to patients with cancer and autoimmune diseases.
No named decision-maker yet.
No careers mailbox known
Jul 1
Won a grant $567k · CORDIS
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline. See how.
No named decision-maker yet.
No careers mailbox known
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and physicians expect.
No named decision-maker yet.
Careers mailbox is known
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance to today's payloads and expand ADC indications. Today we're solving for resistance to existing treatments in cancer.
Maureen Hillenmeyer · Executive Officer, Director · decision-maker
Brian Naughton · Executive Officer, Director · decision-maker
Colin James Harvey · Executive Officer, Director · decision-maker
Jakob Loven · Director
Careers mailbox is known
Nov 26, 2024
Board appointment Hexagon Bio Appoints Yujiro Hata to Board of Directors · YahooFinance
Feb 13, 2023
Raised a round Series B $77.3M · YahooFinance
2016
Founded
1 open
$325k stated pay, 1 roles
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation of disease-causing proteins, with the potential to offer transformative treatment for patients with serious diseases.
No named decision-maker yet.
Careers mailbox is known
Jul 30
Partnership Atavistik Bio Partners With Cure HHT Clinical Trial Network To Advance Development Of ATV-1601 For Hereditary Hemorrhagic Telangiectasia · menafn
Dec 17, 2025
Raised a round Series B $120M
Sep 15, 2025
New executive Atavistik Bio Expands Leadership Team with Appointment ofSusan Pandya, M.D., as Chief Medical Officer · YahooFinance
2021
Founded
A bold visionfor genetic medicines AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common conditions The.
Paul Vogel · Executive Officer, Director · decision-maker
Thorsten Stafforst · Executive Officer, Director · decision-maker
Jin Billy Li · Executive Officer, Director · decision-maker
Careers mailbox is known
Sep 23
Hiring 1 new role, 1 closed in 14 days
Jun 2
New executive AIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company Growth · airna.com
Apr 1
Raised a round Series B $155M
Sep 19, 2023
Launched AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases · businesswire.com
2021
Founded
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
June Lee · Executive Officer, Director · decision-maker
Roy Hardiman · Executive Officer · decision-maker
Jorn Drappa · Executive Officer · decision-maker
David Goldstein · Executive Officer · decision-maker
Careers mailbox is known
Sep 30
Hiring 3 closed in 14 days
Jul 17, 2024
Raised a round Venture round $40M · SEC Form D
2021
Founded
3 open
$148k stated pay, 2 roles
truth B 75 100% stale
